Addictive potentials of antidepressant drugs

Antidepressants: Pharmacology, Health Effects and Controversy

Volumn , Issue , 2012, Pages 27-48

  Bou Khalil, R ^a  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892082142     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (91)

1. Priest, RG, Vize C, Roberts, A, Roberts, M, Tylee, A.Lay people's attitudes to treatment of depression: results of opinion poll for Defeat Depression Campaign just before its launch. BMJ, 1996, 313: 858-859.
2. Gray R, Plummer S, Ritter S Sandford T, Ritter S, Mundt-Leach R, Goldberg D, Gournay K.National survey of practice nurses. J. Advanced Nursing, 1999, 30: 901-906.
3. Kessing LV, Hansen HV, Demyttenaere K, Bech P.Depressive and bipolar disorders: patients' attitudes and beliefs towards depression and antidepressants. Psychological Medicine, 2005, 35: 1205-1213.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders text revision (DSM-IV-TR). Fourth edition. Washington, DC: American Psychiatric Association; 2000.
5. Heather, N.A conceptual framework for explaining drug addiction. Journal of psychopharmacology, 1998, 12: 3-7.
6. Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux, M, Rosenbaum, JF, Young, AH, Zajecka, J.Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Journal of clinical psychiatry, 1997, 58: 5-10.
7. Lane, RM. Withdrawal symptoms after discontinuation of selective serotonin reuptake inhibitors (SSRIs). Journal of serotonin research, 1996, 3/2:75-83.
8. Manna, M, Macpherson, AS. Clinical experience with imipramine in the treatment of depression. Canadian psychiatric association Journal, 1959, 4: 3847.
9. Andersen, H, Kristiansen, ES.Tofranil treatment of endogenous depressions. Acta psychiatrica scandinavica 1959, 34: 386-397.
10. Kramer, JC , Klein, DF, Fink, M .Withdrawal symptoms following discontinuation of imipramine therapy. American Journal of psychiatry, 1961, 118: 549-550.
11. Ali, S, Milev, R.Switch to mania upon discontinuation of antidepressants in patients with mood disorders: a review of the literature. Canadian Journal of Psychiatry, 2003, 48: 258-264.
12. Disalver, SC.Withdrawal phenomena associated with antidepressant and antipsychotic agents. Drug safety, 1994, 10: 103-114.
13. Coupland, NJ, Bell, CJ, Potokar, JP.Serotonin reuptake inhibitor withdrawal. Journal of clinical psychopharmacology, 1996, 16: 356-362.
14. Dilsaver, SC, Greden, JF .Antidepressant withdrawal phenomena. Biological psychiatry, 1984, 19: 237-256.
15. Liskin, B, Roose, S, Walsh, T.Acute psychosis following phenelzine discontinuation. Journal of clinical psychopharmacology, 1984, 5: 46-47.
16. Halle, MT, Dilsaver, SC.Tranylcypromine withdrawal phenomena. Journal of psychiatry and neuroscience, 1993, 18: 49-50.
17. Rothschild, AJ.Mania after withdrawal of isocarboxazid. Journal of clinical psychopharmacology, 1985, 5: 340-342.
18. Vartzopulos, D, Krull, F.Dependence on monoamine oxidase inhibitors in high dose. Bristish journal of psychiatry, 1991, 158: 856-857.
19. Cooper, GL. The safety of fluoxetine: an update. British Journal of psychiatry,1988, 153: 77-86.
20. Black, K, Shea, C, Dursun, S, Kutcher, S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. Journal of psychiatry and neuroscience, 2000, 25:255-261.
21. Hindmarch, I, Kimber, S, Cockle, SM.Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. International clinical psychopharmacology, 2000, 15: 305-318.
22. Michelson, D, Fava, M, Amsterdam, J, Apter, J, Londborg, P, Tamura, R, Tepner, RG.Interruption of selective serotonin reuptake inhibitor treatment. British Journal of psychiatry, 2000, 176: 363-368.
23. Black, K, Shea, C, Dursun, S, Kutcher, S.Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. Journal of psychiatry and neuroscience, 2000, 25: 255-261.
24. Bogetto, F, Bellino, S, Revello, RB, Patria, L.Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation. CNS drugs, 2002, 16: 273-283.
25. Rosenbaum, JF, Fava, M, Hoog, SL, Ascroft, RC, Krebs, WB.Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biological psychiatry, 1998, 44: 77-87.
26. Oehrberg, S, Christiansen, PE, Behnke, K, Borup, AL, Severin, B, Soegaard, J, Calberg, H, Judge, R, Ohrstrom, JK, Manniche, PM.Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. British Journal of psychiatry, 1995, 167: 374-379.
27. Black, K, Shea, C, Dursun, S, Kutcher, S.Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. Journal of psychiatry and neuroscience, 2000, 25: 255-261.
28. Olver, JS, Burrows, GD, Norman, TR.Discontinuation syndromes with selective serotonin reuptake inhibitors. Are there clinically relevant differences? CNS drugs, 1999, 12: 171-177.
29. Lejoyeux, M, Ades, J.Antidepressant discontinuation: a review of the literature. Journal of clinical psychiatry, 1997, 58: 11-16.
30. Dominguez, RA, Goodnick, W.Adverse events after the abrupt discontinuation of paroxetine. Pharmacotherapy, 1995, 15: 778-780.
31. Benazzi, F.Venlafaxine withdrawal symptoms. Canadian Journal of psychiatry, 1996, 41: 487-484.
32. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary, Section 4. 3: Antidepressant drugs: withdrawal. London: The Pharmaceutical Press; 2000.
33. Drug and Therapeutics Bulletin.Withdrawing patients from antidepressants. Drug and therapeutics bulletin, 1999, 37: 49-52.
34. Rosenbaum, JF, Zajecka, J.Clinical management of antidepressant discontinuation. Journal of clinical psychiatry, 1997, 58: 37-40.
35. Louie, AK, Lannon, RA, Kirsch, MA, Louis, TB. Venlafaxine withdrawal reactions. American Journal of psychiatry, 1996, 153: 1652.
36. Fava, M, Mulroy, R, Alpert, J, Nierenberg, AA, Rosenbaum, JF.Emergence of adverse effects following discontinuation of treatment with extended-release venlafaxine. American journal of psychiatry, 1997, 154: 1760-1762.
37. Giakas, WJ, Davis, SM.Intractable withdrawal from venlafaxine treated with fluoxetine. Psychiatric annals, 1997, 27: 85-86.
38. Haddad, P.Newer antidepressant and the discontinuation syndrome. Journal of clinical psychiatry, 1997, 58: 17-22.
39. Boyd, IW. Venlafaxine withdrawal reactions. The med Journal of Australia, 1998, 169:91-92.
40. Sabljić, V, Ružić, K, Rakun, R.Venlafaxine withdrawal syndrome. Psychiatria Danubina, 2011, 23: 117-119.
41. Koga, M, Kodaka, F, Miyata, H, Nakayama, K.Symptoms of delusion: the effects of discontinuation of low-dose venlafaxine. Acta psychiatrica scandinavica, 2009, 120: 329-331.
42. Benazzi, F.Nefazodone withdrawal symptoms. Candian journal of psychiatry, 1998, 43: 194-195.
43. Lauber, C.Nefazodone withdrawal symptoms. Canadian Journal of psychiatry, 1999, 44: 285-286.
44. MacCall, C, Callender, J. Mirtazapine withdrawal causing hypomania. British Journal psychiatry, 1999, 175: 390.
45. Perahia, DG, Kajdasz, DK, Desaiah, D, Haddad, PM.Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. Journal of affect disorders, 2005, 89: 207-212.
46. Pitchot, W, Ansseau, M. Shock-like sensations associated with duloxetine discontinuation. Annals of clinical psychiatry, 2008, 20: 175.
47. Leib, J, Balter, A.Antidepressant tachyphylaxis. Medical hypothesis, 1984, 15: 279-291.
48. Stedman, TL. Stedman's Medical Dictionary. 27th edition. Philadelphia: Lippincott, Williams, and Wilkins; 2000.
49. Solomon, DA, Leon, AC, Mueller, TI, Coryell, W, Teres, JJ, Posternak, MA, Judd, LL, Endicott, J, Keller, MB.Tachyphylaxis in unipolar major depressive disorder. Journal of clin psychiatry, 2005, 66: 283-290.
50. Byrne, S, Rothschild, A. Loss of antidepressant efficacy during maintenance therapy: Possible mechanisms and treatments. Journal of clinical psychiatry, 1998; 59: 279-288.
51. Rothschild, A.The Rothschild Scale for Antidepressant Tachyphylaxis: Reliability and validity. Comprehensive psychiatry, 2008, 49: 508-513.
52. Byrne, S, Rothschild, A.Loss of antidepressant efficacy during maintenance therapy: Possible mechanisms and treatments. Journal of clinical psychiatry, 1998, 59: 279-288.
53. Quitkin, FM, Stewart, JW, McGrath, PJ, Nunes, E, Ocepek-Welikson, K, Tricamo, E, Rabkin, JG, Klein, DF.Further evidence that a placebo response to antidepressants can be identified. American journal of psychiatry, 1993, 150: 562-565.
54. Posternak, MA, Zimmerman, M.Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: A retrospective study. Journal of clinical psychiatry, 2005, 66: 705-707.
55. Wijkstra, J, Burger, H, van den Broek, WW, Birkenhäger, TK, Janzing, JG, Boks, MP, Bruijn, JA, van der Loos, ML, Breteler, LM, Verkes, RJ, Nolen, WA.Long-term response to successful acute pharmacological treatment of psychotic depression. Journal of affective disorders, 2010, 123: 238-242.
56. Kornstein, SG.Beyond remission, rationale, and design of the prevention of recurrent episodes of depression with venlafaxine for two years (PREVENT) Study. CNS spectrums, 2006, 11: 28-34.
57. Neumeister, A, Hu, XZ, Luckenbaugh, DA, Schwarz, M, Nugent, AC, Bonne, O, Herscovitch, P, Goldman, D, Drevets, WC, Charney, DS.Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Archives of general psychiatry, 2006, 63: 978-986.
58. Yoshimura, R, Hori, H, Ikenouchi-Sugita, A, Umene-Nakano, W, Ueda, N, Nakamura, J.Higher plasma interleukin-6 (IL-6) level is associated with SSRI-or SNRI-refractory depression. Progress in neuropsychopharmacology and biological psychiatry, 2009, 33: 722-726.
59. Fava, GA. Can long-term treatment with antidepressant drugs worsen the course of depression? Journal of clinical psychiatry, 2003, 64: 123-133.
60. Muraki, I, Inoue, T, Hashimoto, S, Izumi, T, Koyama, T.Effect of different challenge doses after repeated citalopram treatment on extracellular serotonin level in the medial prefrontal cortex: In vivo microdialysis study. Psychiatry and clinical neuroscience, 2008, 62: 568-574.
61. Amsterdam, J, Williams, D, Michelson, D, Adler, LA, Dunner, DL, Nierenberg, AA, Reimherr, FW, Schatzberg, AF.Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. Neuropsychobiology, 2009, 59: 227-233.
62. Sharma, V.Loss of response to antidepressants and subsequent refractoriness: Diagnostic issues in a retrospective case series. Journal of affective disorders, 2001, 64: 99-106.
63. Charlier, C, Pinto, E, Ansseau, M, Plomteux, G.Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Human psychopharmacology, 2000, 15: 453-459.
64. Byrne, S, Rothschild, AJ.Psychiatrists' responses to failure of maintenance therapy with antidepressants. Psychiatric services, 1997, 48: 835-837.
65. Fava, M, Rappe, SM, Pava, JA, Nierenberg, AA, Alpert, JE, Rosenbaum, JF.Relapse in patients on long-term fluoxetine treatment:Response to increased fluoxetine dose. Journal of clinical psychiatry, 1995, 56: 52-55.
66. Cain, JW.Poor response to fluoxetine: Underlying depression, serotonergic overstimulation, or a "therapeutic window. " Journal of clinical psychiatry, 1992, 53: 272-277.
67. Haddad, P. Do antidepressants have any potential to cause addiction? Journal of psychopharmacology, 1999, 13: 300-307.
68. Bertschy, G, Luxembourger, I, Bizouard, P, Vandel, S, Allers, G, Volmat, R. [Amineptin dependence. Detection of patients at risk. Report of 8 cases]. Encephale, 1990, 16:405-409.
69. Perera, I, Lim, L.Amineptine and midazolam dependence. Singapore medical Journal, 1998, 39: 129-131.
70. Kisa, C, Bulbul, DO, Aydemir, C, Goka, E.Is it possible to be dependent to Tianeptine, an antidepressant? A case report. Progress in neuropsychopharmacology and biological psychiatry, 2007, 31: 776-778.
71. Quaglio, G, Schifano, F, Lugoboni, F.Venlafaxine dependence in a patient with a history of alcohol and amineptine misuse. Addiction, 2008, 103: 1572-1574.
72. Vandel, P, Regina, W, Bonin, B, Sechter, D, Bizouard, P.[Abuse of tianeptine. A case report]. Encephale, 1999, 25: 672-673.
73. Saatçioǧlu, O, Erim, R, Cakmak, D.[A case of tianeptine abuse]. Turkish Journal of psychiatry, 2006, 17: 72-75.
74. Kim, D, Steinhart, B.Seizures induced by recreational abuse of bupropion tablets via nasal insufflation. CJEM, 2010, 12: 158-161.
75. Langguth, B, Hajak, G, Landgrebe, M, Unglaub, W.Abuse potential of bupropion nasal insufflation: a case report. Journal of clinical psychopharmacology, 2009, 29: 618-619.
76. Vetulani, J.Drug addiction. Part II. Neurobiology of addiction. Polish Journal of pharmacology, 2001, 53: 303-317.
77. Gardner, EL.Addiction and brain reward and antireward pathways. Advnces in psychosomatic medicine, 2011, 30: 22-60.
78. Zawertailo, LA, Busto, UE, Kaplan, HL, Greenblatt, DJ, Sellers, EM.Comparative abuse liability of sertraline, alprazolam and dextroamphetamine in humans. Journal of clinical psychopharmacology, 1995, 15: 117-124.
79. Gold, LH, Balster, RL.Evaluation of nefazodone self-administration in rhesus monkeys. Drugs and alcohol dependence, 1991, 28: 241-247.
80. Oswald, I, Brezinova, V, Dunleavy, DLF.On the slowness of action of tricyclic antidepressant drugs. British Journal of pychiatry, 1972, 120: 673-677.
81. Moreno Brea, MR, Rojas Corrales, O, Gibert-Rahola, J, Micó, JA.[Drug interactions of methadone with CNS-active agents]. Actas espanolas de psiquiatria, 1999, 27: 103-110.
82. Eschalier, A, Ardid, D, Coudore, F. Pharmacological studies of the analgesic effect of antidepressants. Clinical Neuropharmacology, 1992, 15: 373A-374A.
83. Banks, ML, Rice, KC, Negus, SS.Antinociceptive interactions between Mu-opioid receptor agonists and the serotonin uptake inhibitor clomipramine in rhesus monkeys: role of Mu agonist efficacy. Journal of pharmacology and experimental therapeutics, 2010, 335: 497-505.
84. Cohen, MJ, Hanbury, R, Stimmel, B.Abuse of amitriptyline. JAMA, 1978, 240: 1372-1373.
85. Dorman, A, Byrne, P, Talbot, D, O'Connor, J. Misuse of dothiepin. BMJ, 1995, 311: 1502.
86. Darke, S, Ross, J.The use of antidepressants among injecting drug users in Sydney, Australia. Addiction, 2000, 95: 407-417.
87. Peles, E, Schreiber, S, Adelson, M.Tricyclic antidepressants abuse, with or without benzodiazepines abuse, in former heroin addicts currently in methadone maintenance treatment (MMT). European neuropsychopharmacology, 2008, 18: 188-193.
88. Samanin, R, Jori, A, Bernasconi, S, Morpugo, E, Garattini, S.Biochemical and pharmacological studies on amineptine (S 1964) and (+) amphetamine in the rat. Journal of pharmacy and pharmacology, 1997, 29: 555-558.
89. Ponzio, F, Achilli, G, Garattinni, S, Perego, C, Sacchetti, G, Algeri, S.Amineptine: its effects on the dopaminergic system of rats. Journal of pharmacy and pharmacology, 1986, 38: 301-303.
90. Mercuri, NB, Federici, M, Marinelli, S, Bernardi, G.Tranylcypromine, but not moclobemide, prolongs the inhibitory action of dopamine on midbrain dopaminergic neurons: an in vitro electrophysiological study. Synapse, 2000, 37: 216-221.
91. Learned-Coughlin, SM, Bergström, M, Savitcheva, I, Ascher, J, Schmith, VD, Långstrom, B.In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biological psychiatry, 2003, 54: 800-805.